{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:34:39Z","timestamp":1790674479392,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS28721"],"award-info":[{"award-number":["NS28721"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.neulet.2021.136180","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T13:22:07Z","timestamp":1629206527000},"page":"136180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2\/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6\/2 Huntington\u2019s disease mice"],"prefix":"10.1016","volume":"763","author":[{"given":"H.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Del Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neulet.2021.136180_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2012.03.025","article-title":"The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6\/2 Huntington\u2019s disease mice","volume":"47","author":"Reiner","year":"2012","journal-title":"Neurobiol. Disease"},{"key":"10.1016\/j.neulet.2021.136180_b0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.brainres.2012.07.026","article-title":"BDNF may play a differential role in the protective effect of the mGluR2\/3 agonist LY379268 on striatal projection neurons in R6\/2 Huntington's disease mice","volume":"1473","author":"Reiner","year":"2012","journal-title":"Brain Res"},{"key":"10.1016\/j.neulet.2021.136180_b0015","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neulet.2021.136180_b0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1750-3639.2007.00111.x","article-title":"Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington\u2019s disease","volume":"18","author":"Zuccato","year":"2008","journal-title":"Brain Path."},{"key":"10.1016\/j.neulet.2021.136180_b0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-3-642-45106-5_14","article-title":"Huntington\u2019s disease","volume":"220","author":"Zuccato","year":"2014","journal-title":"Handbook Experimental Pharmacol."},{"key":"10.1016\/j.neulet.2021.136180_b0030","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1523\/JNEUROSCI.3920-03.2004","article-title":"Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor","volume":"24","author":"Baquet","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2021.136180_b0035","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1523\/JNEUROSCI.1197-04.2004","article-title":"Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington\u2019s disease","volume":"24","author":"Canals","year":"2004","journal-title":"J. Neurosci."},{"issue":"43","key":"10.1016\/j.neulet.2021.136180_b0040","doi-asserted-by":"crossref","first-page":"11758","DOI":"10.1523\/JNEUROSCI.2461-07.2007","article-title":"Expression profiling of Huntington\u2019s disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration","volume":"27","author":"Strand","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2021.136180_b0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1471-4159.2007.05137.x","article-title":"BDNF overexpression in the forebrain ameliorates huntington\u2019s disease phenotypes in mice","volume":"105","author":"Gharami","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2021.136180_b0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1326-6-71","article-title":"Conditional BDNF release under pathological conditions E.D., improves Huntington\u2019s disease pathology by delaying neuronal dysfunction","volume":"6","author":"Giralt","year":"2011","journal-title":"Molec. Neurodegen."},{"issue":"44","key":"10.1016\/j.neulet.2021.136180_b0055","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","article-title":"BDNF Overexpression in the forebrain rescues Huntington\u2019s disease phenotypes in YAC128 mice","volume":"30","author":"Xie","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2021.136180_b0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nbd.2013.08.009","article-title":"Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington\u2019s disease mice","volume":"60","author":"Deng","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.neulet.2021.136180_b0065","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/cne.23235","article-title":"Confocal laser scanning microscopy and ultrastructural study of VGLUT2 thalamic input to striatal projection neurons in rats","volume":"521","author":"Lei","year":"2013","journal-title":"J. Comp. Neurol."},{"issue":"6653","key":"10.1016\/j.neulet.2021.136180_b0070","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/39885","article-title":"Anterograde transport of brain-derived neurotrophic factor and its role in the brain","volume":"389","author":"Altar","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neulet.2021.136180_b0075","doi-asserted-by":"crossref","unstructured":"P. Samadi A. Boutet V.V. Rymar K. Rawal J. Maheux J.-C. Kvann M. Tomaszewski F. Beaubien J.F. Cloutier D. Levesque A.F. Sadikot Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6\/2 mouse model of Huntington's disease 12 1 2013 108 124.","DOI":"10.1111\/j.1601-183X.2012.00858.x"},{"key":"10.1016\/j.neulet.2021.136180_b0080","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cns.12844","article-title":"Disrupted striatal inputs and outputs in Huntington\u2019s disease","volume":"24","author":"Reiner","year":"2018","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.neulet.2021.136180_b0085","unstructured":"Allen Brain Atlas, http, \/\/mouse.brain-map.org\/welcome.do."},{"key":"10.1016\/j.neulet.2021.136180_b0090","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/cne.25023","article-title":"Progression of basal ganglia pathology in heterozygous Q175 knock-in Huntington's disease mice","volume":"529","author":"Deng","year":"2021","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neulet.2021.136180_b0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0301-0082(03)00019-4","article-title":"Neurotrophin secretion: current facts and future prospects","volume":"69","author":"Lessmann","year":"2003","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.neulet.2021.136180_b0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/35049004","article-title":"Neurotrophins as synaptic modulators","volume":"2","author":"Poo","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.neulet.2021.136180_b0105","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1073\/pnas.1004744108","article-title":"TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons","volume":"108","author":"Baydyuk","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.neulet.2021.136180_b0110","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s10571-011-9725-y","article-title":"Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype","volume":"31","author":"Arregui","year":"2011","journal-title":"Cell. Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.neulet.2021.136180_b0115","doi-asserted-by":"crossref","first-page":"e64037","DOI":"10.1371\/journal.pone.0064037","article-title":"Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6\/2 mouse model of Huntington\u2019s Disease","volume":"8","author":"Giamp\u00e0","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2021.136180_b0120","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s12035-019-01847-8","article-title":"Neuroprotective effects of doxycycline in the R6\/2 mouse model of Huntington\u2019s disease","volume":"57","author":"Paldino","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neulet.2021.136180_b0125","doi-asserted-by":"crossref","unstructured":"S. Gin\u00e9s, M. Bosch, S. Marco, N. Gavald\u00e0, M. D\u00edaz-Hern\u00e1ndez, J.J. Lucas, J.M. Canals, J. Alberch, Reduced expression of the TrkB receptor in Huntington\u2019s disease mouse models and in human brain, Europ. J. Neurosci. 23 (2006) 649-658.","DOI":"10.1111\/j.1460-9568.2006.04590.x"},{"key":"10.1016\/j.neulet.2021.136180_b0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fncel.2016.00037","article-title":"Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6\/2 mouse model of Huntington\u2019s Disease","volume":"10","author":"Nguyen","year":"2016","journal-title":"Front. Cellular Neurosci."},{"issue":"2011","key":"10.1016\/j.neulet.2021.136180_b0135","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","article-title":"Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function","volume":"198","author":"Raymond","year":"2011","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.neulet.2021.136180_b0140","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","article-title":"Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease","volume":"33","author":"Zeron","year":"2002","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.neulet.2021.136180_b0145","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0028-3908(99)00092-1","article-title":"Pharmacological agents acting at subtypes of metabotropic glutamate receptors","volume":"38","author":"Schoepp","year":"1999","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.neulet.2021.136180_b0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0304-3940(97)00442-4","article-title":"In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740","volume":"229","author":"Battaglia","year":"1997","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.neulet.2021.136180_b0155","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1152\/jn.1995.73.3.1076","article-title":"Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3","volume":"73","author":"Lovinger","year":"1995","journal-title":"J. Neurophys."},{"key":"10.1016\/j.neulet.2021.136180_b0160","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0014-2999(99)00397-0","article-title":"Neuroprotection by metabotropic glutamate receptor agonists: LY2354740, LY379268 and LY389795","volume":"377","author":"Kingston","year":"1990","journal-title":"Europ. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neulet.2021.136180_b0165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2010.01.008","article-title":"Early Increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice","volume":"65","author":"Milnerwood","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2021.136180_b0170","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jchemneu.2004.02.005","article-title":"Differential loss of striatal projection neurons in Huntington's disease: A quantitative immunohistochemical study","volume":"27","author":"Deng","year":"2004","journal-title":"J. Chem. Neuroanat."},{"issue":"3","key":"10.1016\/j.neulet.2021.136180_b0175","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.neuroscience.2009.11.012","article-title":"Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain","volume":"165","author":"Di Liberto","year":"2010","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neulet.2021.136180_b0180","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0959-4388(03)00073-4","article-title":"Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation","volume":"13","author":"Vanhoutte","year":"2003","journal-title":"Current Opinion Neurobiol."},{"key":"10.1016\/j.neulet.2021.136180_b0185","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13195-017-0307-1","article-title":"Gene suppression approaches to neurodegeneration","volume":"9","author":"Ghosh","year":"2017","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"2","key":"10.1016\/j.neulet.2021.136180_b0190","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.nbd.2011.12.030","article-title":"Gene therapy for Huntington's disease","volume":"48","author":"Ramaswamy","year":"2012","journal-title":"Neurobiol. Disease"},{"issue":"6","key":"10.1016\/j.neulet.2021.136180_b0195","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington\u2019s Disease models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"issue":"2017","key":"10.1016\/j.neulet.2021.136180_b0200","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JHD-170262","article-title":"Clinical Trials Corner: September 2017","volume":"6","author":"Rodrigues","year":"2017","journal-title":"J. Huntingtons Disease"},{"key":"10.1016\/j.neulet.2021.136180_b0205","doi-asserted-by":"crossref","unstructured":"C.D. Johnson, B.L. Davidson, Huntington's disease: progress toward effective disease-modifying treatments and a cure, Hum. Mol. Genet. 9 (R1), R98\u2013R102.","DOI":"10.1093\/hmg\/ddq148"},{"key":"10.1016\/j.neulet.2021.136180_b0210","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/d41586-021-01177-7","article-title":"Genetic therapies for Huntington\u2019s disease fail in clinical trials","volume":"593","author":"Kwon","year":"2021","journal-title":"Nature"}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394021005589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394021005589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:41:32Z","timestamp":1759610492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394021005589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":42,"alternative-id":["S0304394021005589"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2021.136180","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2\/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6\/2 Huntington\u2019s disease mice","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2021.136180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"136180"}}